CORTEXIN
Cortexin is a complex of water-soluble neuropeptides isolated from the cerebral cortex of cattle and pigs, used clinically in Russia for neuroprotection in traumatic brain injury, ischemic stroke recovery, pediatric cognitive disorders, and age-related neurodegeneration.
Cortexin is a complex of water-soluble neuropeptides with molecular weights up to 10 kDa, isolated from the cerebral cortex of cattle and pigs through a standardized extraction process. Developed at the Institute of Bioregulation and Gerontology in Saint Petersburg and registered as a pharmaceutical product in Russia since 1999, Cortexin is one of the most widely prescribed neuroprotective agents in Russian clinical practice.
Overview
Cortexin occupies a central position in Russian neuroprotective pharmacotherapy, where it has been used continuously since its registration in 1999. The preparation emerged from the same bioregulatory research program that produced Retinalamin (retinal extract), Epithalamin (pineal extract), and Thymalin (thymic extract) — each representing the tissue-specific bioregulator approach applied to different organ systems.
The clinical experience with Cortexin is extensive: it has been prescribed to millions of patients in Russia and CIS countries across neurological, neurosurgical, and pediatric neurology indications. Its use in pediatric populations — including neonates with perinatal CNS pathology — is particularly notable, as few neuroprotective agents have comparable pediatric safety records. The pharmacological profile combines neurotrophic support, antioxidant protection, anti-inflammatory activity, and anti-excitotoxic effects, reflecting the multi-component nature of the preparation.
While Cortexin's evidence base consists primarily of Russian clinical studies that do not meet Western regulatory standards for randomized controlled trials, the volume and consistency of clinical reports over 25 years provide substantial pragmatic evidence for its clinical utility and safety profile.
Mechanism of Action
Cortexin's polypeptide complex exerts neuroprotective effects through multiple complementary mechanisms, reflecting the multi-component nature of the cerebral cortex extract.
BDNF and NGF upregulation: Cortexin stimulates the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in neural tissue. Granstrem et al. (2008) demonstrated that Cortexin treatment increases BDNF and NGF levels in rat brain tissue, supporting neuronal survival, synaptic plasticity, and axonal regeneration. BDNF signaling through the TrkB receptor activates downstream PI3K/Akt and MAPK/ERK survival pathways, while NGF acts through TrkA to support cholinergic neuron function — a pathway directly relevant to cognitive performance and Alzheimer's disease pathology.
GABAergic modulation: Cortexin modulates GABAergic neurotransmission, enhancing the inhibitory tone of neural circuits. Studenikin et al. (2014) reported that Cortexin normalizes the excitatory-inhibitory balance in children with epilepsy and ADHD, reducing seizure frequency and improving behavioral regulation. This GABAergic modulation is proposed to occur through upregulation of GABA receptor subunit expression and enhanced GABA synthesis via glutamic acid decarboxylase (GAD) gene expression.
Antioxidant enzyme induction: Cortexin upregulates the expression and activity of endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx). Skoromets et al. (2012) demonstrated reduced levels of lipid peroxidation products (malondialdehyde, 4-hydroxynonenal) and increased antioxidant enzyme activity in patients treated with Cortexin following ischemic stroke. This antioxidant mechanism is critical in the post-ischemic brain, where reperfusion injury generates massive oxidative stress through mitochondrial dysfunction and activation of NADPH oxidase.
Anti-apoptotic signaling: The peptide complex modulates the balance between pro-apoptotic and anti-apoptotic factors in neurons. Cortexin upregulates Bcl-2 and Bcl-xL while reducing expression of Bax, Bad, and active caspase-3 in neural tissue exposed to ischemic or traumatic injury. This shift in the apoptotic balance reduces delayed neuronal death — a major contributor to secondary brain injury following TBI and stroke.
Glutamate excitotoxicity protection: Excitotoxicity mediated by excessive glutamate signaling through NMDA receptors is a primary mechanism of neuronal death following ischemic stroke and TBI. Cortexin provides protection against excitotoxicity through multiple mechanisms: modulation of glutamate transporter expression (EAAT1/GLAST, EAAT2/GLT-1) to enhance glutamate clearance, support of astrocytic glutamate uptake function, and stabilization of neuronal calcium homeostasis. Belousova et al. (2014) demonstrated that Cortexin reduces glutamate-induced neuronal death in cell culture models.
Neuroinflammation modulation: Cortexin modulates microglial activation and reduces pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6) in the injured brain. By shifting microglial polarization from the neurotoxic M1 phenotype toward the neuroprotective M2 phenotype, Cortexin reduces secondary inflammatory damage that exacerbates primary neurological injury.
Reconstitution Calculator
CORTEXIN
**Cortexin** is a complex of water-soluble neuropeptides with molecular weights
Exceeds syringe capacity
Dose requires 2.000mL but syringe holds 1mL. Increase BAC water, use a larger syringe, or split injections.
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Reported Effects
Post-Viral Recovery:: High success rates in treating neurological symptoms of Post-COVID syndrome according to clinical data.. Pediatric Memory:: Clinically proven to be more effective than some standard synthetic nootropics for childhood memory disorders.. Rapid Onset:: Many users report feeling a 'lifting' of mental heaviness within the first few days of a cycle.
- High success rates in treating neurological symptoms of Post-COVID syndrome according to clinical data.
- Clinically proven to be more effective than some standard synthetic nootropics for childhood memory disorders.
- Many users report feeling a 'lifting' of mental heaviness within the first few days of a cycle.
Safety Profile
Cortexin has one of the most extensive pediatric and adult safety records among neuroprotective agents in Russian clinical practice, spanning over 25 years of continuous pharmaceutical use since its registration in 1999. The safety profile is favorable across all age groups from neonates to elderly patients.
Key safety considerations include:
- General tolerability: Very well tolerated across age groups. The most common adverse effect is mild pain at the IM injection site, which can be reduced by reconstitution in 0.5% procaine instead of saline.
- Allergic reactions: Rare hypersensitivity reactions have been reported, primarily in patients with known sensitivity to animal-derived proteins. Anaphylactic reactions are extremely rare but theoretically possible given the bovine/porcine origin of the preparation.
- Pediatric safety: Extensively used in neonatal and pediatric populations with a favorable safety record. The dosing is weight-adjusted (0.5 mg/kg for children under 20 kg) to account for pediatric pharmacokinetic differences. No growth, development, or endocrine adverse effects have been reported with repeated courses.
- Pregnancy and lactation: Contraindicated during pregnancy and lactation as a precautionary measure due to insufficient reproductive safety data, though no teratogenic or embryotoxic effects have been reported.
- Drug interactions: No clinically significant drug interactions have been reported. Cortexin is routinely used alongside anticonvulsants, anticoagulants, antihypertensives, and other medications prescribed in neurological practice.
- Long-term safety: The repeated-course protocol (multiple 10-day courses per year over years) has been used without evidence of cumulative toxicity, immune sensitization, or tolerance development.
- Contraindications: Known hypersensitivity to Cortexin components. Caution in patients with severe allergic history, particularly to animal-derived products.
- Prion safety: Modern manufacturing includes ultrafiltration steps designed to remove potential prion proteins, addressing the theoretical risk associated with bovine-derived biological products. Porcine source material is considered lower risk for transmissible spongiform encephalopathies than bovine.
Pharmacokinetic Profile
- Half-life
- Short (peptide mixture, rapidly degraded)
- Metabolism
- Polypeptide components are degraded by serum and tissue peptidases to constituent amino acids. Smaller peptide fragments may retain bioactivity during the degradation process, extending the effective pharmacodynamic window beyond the parent compound half-life.
- Distribution
- As a complex polypeptide mixture, Cortexin components distribute based on molecular weight, charge, and tissue affinity. The tissue-specific bioregulator model proposes that cerebral cortex-derived peptides show preferential accumulation in neural tissue, though this has not been formally demonstrated with pharmacokinetic tracing studies. Components below ~500 Da may cross the blood-brain barrier directly, while larger peptide fractions may exert peripheral effects or require active transport mechanisms.
- BBB Penetration
- The low molecular weight of constituent peptides (<10 kDa) facilitates blood-brain barrier crossing for the smaller fraction components. Peptide transporters (PepT2/SLC15A2) expressed in brain endothelium may contribute to active transport of dipeptide and tripeptide components. The extent of CNS penetration for individual peptide components has not been fully characterized.
- Oral
- Parenteral (IM) administration provides complete systemic bioavailability. Not orally bioavailable due to GI peptidase degradation of the polypeptide components. No oral formulation is available.
Quick Start
- Typical Dose
- 10mg administered via intramuscular injection once daily for 10 days.
- Route
- Intramuscular injection
Research Protocols
intramuscular Injection
Clinical Research Protocols - Adults (standard protocol): 10 mg Cortexin lyophilized powder reconstituted in 1-2 mL 0.9% sodium chloride or 0.5% procaine (for pain reduction at injection site), administered intramuscularly once daily for 10 days. - Children (standard protocol): 5 mg Cortexin recons
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Pediatric safety | 0.5 mg | Per protocol | — |
| Children (standard protocol) | 5 mg, 0.5 mg | Once daily | 10 days(Route: Intramuscular Injection) |
| Neonates and infants | 0.5 mg | Per protocol | 10 days |
Interactions
Peptide Interactions
BDNF and NGF upregulation: Cortexin stimulates the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in neural tissue.
What to Expect
What to Expect
Acute stroke timing: Best outcomes reported when treatment is initiated within 6-24 hours of stroke onset, alongside standard stroke care.
Patients receiving Cortexin (10 mg IM daily for 10 days) in addition to standard stroke care showed significantly greater improvement in NIHSS...
Course repetition: Treatment courses are repeated every 3-6 months depending on clinical indication and response.
Continued use as directed
Safety Profile
Common Side Effects
- Injection Site Pain:: As an intramuscular medication, local irritation or soreness at the injection site is the most common complaint.
- Temporary Irritability:: Some users report mild, transient irritability or 'over-arousal' during the first few days of treatment.
- Anxiogenic Potential:: Animal studies suggest that while acute use is anxiolytic, repeated use may occasionally lead to anxiogenic-like arousal.
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
- Extensive peer-reviewed research base
Caution
- Injection site reactions reported
Frequently Asked Questions
References (15)
- [1]Molecular Mechanisms of the Actions of Brain Peptide-Containing Drugs: Cortexin
→ This study highlights that Cortexin influences neuroplasticity, energy metabolism, and neuroinflammation through multiple neuropeptide signaling pathways.
- [3]Efficacy of Cortexin in the Treatment of Memory Disorders in Children
→ In a comparative trial involving children with memory deficits, Cortexin showed an 86.7% improvement rate, outperforming the reference drug Encephabol.
- [6]Khavinson VK Peptides and Ageing Neuro Endocrinol Lett. (2005)
- [7]Skoromets AA et al Cortexin: new possibilities of neuroprotection and therapy of neurological diseases Neurology, Neuropsychiatry, Psychosomatics. (2012)
- [8]Studenikin VM et al Cortexin in pediatric neurology: experience and perspectives Medical Council. (2014)
- [9]Granstrem OK et al Effect of Cortexin on neurotrophic factor levels in the brain Neurochem J. (2008)
- [10]Belousova MA et al Neuroprotective effects of Cortexin on glutamate-induced neurotoxicity in vitro Neurochem J. (2014)
- [2]Determination of the Prevalence of Postcovid Syndrome and Assessment of the Effectiveness of the Drug Cortexin in the Treatment of Neurological Disorders in Patients with Postcovid Syndrome
→ Clinical observation of nearly 1,000 patients found that Cortexin significantly reduced fatigue, memory loss, and concentration issues in individuals suffering from Post-COVID syndrome.
- [14]Khavinson VK, Lezhava TA, Malinin VV Effects of short peptides on lymphocyte chromatin in senile subjects Bull Exp Biol Med. (2004)
- [15]Lezhava T et al Anti-aging peptide bioregulators induce reactivation of chromatin Georgian Med News. (2006)
- [4]The peptide-based drug cortexin inhibits brain caspase-8
→ Research demonstrates that Cortexin may prevent programmed cell death in the brain by inhibiting specific proteolytic enzymes involved in apoptosis.
- [5]Molecular partners of Cortexin in the brain
→ This study identifies specific molecular targets for Cortexin, including tubulin β5 and creatine kinase B-type, which facilitate its neuroprotective effects.
- [11]Gusev EI, Skvortsova VI Neuronal plasticity and neuroprotection in the acute period of ischemic stroke Zh Nevrol Psikhiatr Im S S Korsakova. (2003)
- [12]Granstrem OK et al Anti-apoptotic effects of Cortexin and its neuroprotective activity Neurosci Behav Physiol. (2010)
- [13]Trofimova SV, Khavinson VK, Kozina LS Peptide bioregulators: tissue-specific effects Bull Exp Biol Med. (2004)
Cortagen
Cortagen is a synthetic tetrapeptide bioregulator (Ala-Glu-Asp-Pro) studied for its effects on central nervous system gene expression, chromatin remodeling, and neuroprotective signaling in neural tissues.
Cortistatin (CST-14 / CST-17)
Cortistatin is a somatostatin-related neuropeptide existing as 14- or 17-amino acid isoforms (CST-14, CST-17). Despite sharing 11 of 14 residues with somatostatin, cortistatin is encoded by a distinct gene and exhibits unique anti-inflammatory, neuromodulatory, and sleep-promoting properties, including binding to the ghrelin receptor (GHSR-1a).